Literature DB >> 32597636

Sequencing a Bispecific Antibody by Controlling Chain Concentration Effects When Using an Immobilized Nonspecific Protease.

Robert A D'Ippolito1, Maria C Panepinto1, Keira E Mahoney1, Dina L Bai1, Jeffrey Shabanowitz1, Donald F Hunt1,2.   

Abstract

Complete sequence coverage of monospecific antibodies was previously achieved using immobilized aspergillopepsin I in a single LC-MS/MS analysis. Bispecific antibodies are asymmetrical compared to their monospecific antibody counterparts, resulting in a decrease in the concentration of individual subunits. Four standard proteins were used to characterize the effect of a decrease in concentration when using this immobilized enzyme reactor. Low concentration samples resulted in the elimination of large peptide products due to a greater number of enzymatic cleavages. A competitive inhibitor rich in arginine residues reduced the number of enzymatic cleavages to the protein and retained large molecular weight products. The digestion of a bispecific antibody with competitive inhibition of aspergillopepsin I maintained large peptide products better suited for sequence reconstruction, resulting in complete sequence coverage from a single LC-MS/MS analysis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32597636      PMCID: PMC8106826          DOI: 10.1021/acs.analchem.0c01126

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  47 in total

1.  Histone H1 and the origin of protamines.

Authors:  John D Lewis; Núria Saperas; Yue Song; Maria Jose Zamora; Manel Chiva; Juan Ausió
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

2.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

Review 3.  Modifying enzyme activity and selectivity by immobilization.

Authors:  Rafael C Rodrigues; Claudia Ortiz; Ángel Berenguer-Murcia; Rodrigo Torres; Roberto Fernández-Lafuente
Journal:  Chem Soc Rev       Date:  2013-08-07       Impact factor: 54.564

4.  Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry.

Authors:  Luca Fornelli; Daniel Ayoub; Konstantin Aizikov; Alain Beck; Yury O Tsybin
Journal:  Anal Chem       Date:  2014-03-03       Impact factor: 6.986

5.  Charge Variant Analysis of Monoclonal Antibodies Using Direct Coupled pH Gradient Cation Exchange Chromatography to High-Resolution Native Mass Spectrometry.

Authors:  Florian Füssl; Ken Cook; Kai Scheffler; Amy Farrell; Stefan Mittermayr; Jonathan Bones
Journal:  Anal Chem       Date:  2018-03-12       Impact factor: 6.986

6.  Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.

Authors:  Leslie A Khawli; Sirj Goswami; Ryan Hutchinson; Zephania W Kwong; Jihong Yang; Xiangdan Wang; Zhenling Yao; Alavattam Sreedhara; Tony Cano; Devin Tesar; Ihsan Nijem; David E Allison; Pin Yee Wong; Yung-Hsiang Kao; Cynthia Quan; Amita Joshi; Reed J Harris; Paul Motchnik
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 7.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Authors:  Peter J Lenting; Cécile V Denis; Olivier D Christophe
Journal:  Blood       Date:  2017-10-17       Impact factor: 22.113

8.  IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.

Authors:  Ulrich von Pawel-Rammingen; Björn P Johansson; Lars Björck
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

9.  Bovine beta-lactoglobulin at 1.8 A resolution--still an enigmatic lipocalin.

Authors:  S Brownlow; J H Morais Cabral; R Cooper; D R Flower; S J Yewdall; I Polikarpov; A C North; L Sawyer
Journal:  Structure       Date:  1997-04-15       Impact factor: 5.006

Review 10.  The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Authors:  Tristan Knight; Michael U Callaghan
Journal:  Ther Adv Hematol       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.